Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android. Learn more here!

α1-Antitrypsin deficiency (AATD) is a relatively common inherited disorder. It primarily presents with early-onset panacinar lung emphysema and with liver cirrhosis in a minority of the patients. Cardiac arrest in association with general anesthesia has been described.

α1-Antiprotease Deficiency; Hereditary Pulmonary Emphysema; AATD.

Worldwide, approximately 1:2000 to 1:4000 newborns have AATD. This disorder is found in all ethnic groups but most frequently in Caucasians.

AATD is inherited in an autosomal recessive pattern. In the majority of patients, the parents are carriers (heterozygous for the defect) but show no symptoms of the disease. A gene called SERPINA1 (Serine [or cysteine] proteinase inhibitor, clade A [AAT], member 1) is responsible for production of AAT and has been mapped to 14q32.1.

The SERPINA1 gene comes in many alleles (>100 different phenotypic variants of AATD have been identified). Most people (approximately 90%) are homozygous for the M version (PiMM, where Pi = proteinase inhibitor), which is characterized by normal levels of AAT (serum levels 20-60 mmol/l). Two altered alleles of the SERPINA1 gene result in moderately low to very low AAT levels and are called the S and Z allele, respectively. Individuals with a PiZZ (AAT serum level 3.3-7 mmol/l) or PiSZ phenotype are at high risk to develop AATD. In fact, the PiZZ phenotype is responsible for almost all the cases of AAT-related emphysema and liver disease. In general, individuals with a PiMS or PiSS genotype can produce enough AAT to prevent lung damage. In general, a serum level of approximately 11 mmol/l and higher is considered sufficient to prevent lung damage. However, patients with the PiMZ genotype (carrier) who smoke are at increased risk for lung disease. In a rare variant, termed the 00 (null-null) phenotype, no AAT is produced.

AAT is a glycoprotein with a molecular weight of 54 kDa. It is produced in hepatocytes and mononuclear phagocytes. The genetic defect in AATD alters the molecule (misfolding secondary to substitution of alanine for valine at amino acid residue 213 and substitution of lysine for glutamate at amino acid residue 342 of AAT) such that, although synthesized, it cannot be released from the endoplasmic reticulum, where a significant part is degraded but the rest accumulates in the form of insoluble intracellular globular inclusions. The inclusion can easily be identified on routine (H and E) and periodic acid-Schiff (PAS)-stained liver biopsies (except in the Pi00 genotype, where AAT production is completely absent). AAT serum levels in PiZZ patients are approximately 10 to 15% of normal values, meaning that 85 to 90% of AAT produced remains intracellularly, of which a significant part is degraded; the rest accumulates. The major function of AAT is inhibition of several mainly neutrophil-derived proteases, particularly at sites of inflammation where high amounts of active serine proteases (elastase, trypsin, cathepsin G, proteinase 3) are released from infiltrating polymorphonuclear cells. ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.